```html

Supraventricular Tachycardia (SVT) – A Comprehensive Guide

Overview

Supraventricular tachycardia (SVT) is a group of heart‑rhythm disorders that originate above the ventricles (the heart’s lower chambers). In SVT, an electrical pathway in the atria or the atrioventricular (AV) node fires rapidly, causing the heart to beat faster than normal—often 150‑250 beats per minute (bpm).

SVT can affect anyone, but it is most common in:

• Young adults and teenagers (especially women)
• People with a family history of abnormal heart rhythms
• Individuals with structural heart disease (e.g., congenital heart defects)

Overall prevalence is estimated at 2–3 per 1,000 people in the United States, with an incidence of about 1 in 500 adults per year (Mayo Clinic; CDC). Although most episodes are brief and benign, recurrent SVT can impair quality of life and, in rare cases, lead to serious complications.

Symptoms

The hallmark of SVT is a sudden, rapid heartbeat that starts and stops abruptly. Symptoms vary widely—some people feel only a brief “flutter,” while others experience distressing palpitations and weakness.

• Palpitations – A sensation of the heart racing, fluttering, or “jumping.”
• Chest discomfort – Pressure, tightness, or mild pain (often described as “non‑cardiac” or “burning”).
• Dizziness or light‑headedness – Due to reduced cardiac output.
• Shortness of breath – Especially during an episode or with exertion.
• Fatigue – Persistent tiredness after frequent episodes.
• Syncope (fainting) – Rare, but indicates a significant drop in blood pressure.
• Arm, neck, or jaw pain – May mimic angina; requires evaluation.
• Anxiety or feeling of impending doom – Often mistaken for panic attacks.
• Heart “skipping” beats – Palpable pauses before the rapid rhythm begins.
• Cold sweats – Autonomic response to rapid heart rate.

Episodes usually last from a few seconds to several hours. In some people, SVT may be triggered by caffeine, alcohol, stress, or certain medications.

Causes and Risk Factors

Underlying Mechanisms

SVT is caused by an abnormal electrical circuit that allows impulses to travel rapidly through the atria or AV node. The most common types include:

• Atrioventricular Nodal Re‑entry Tachycardia (AVNRT) – A re‑entrant loop within the AV node.
• Atrioventricular Re‑entry Tachycardia (AVRT) – Involves an accessory pathway (e.g., Wolff‑Parkinson‑White syndrome).
• Atrial Tachycardia – An ectopic focus in the atrium fires at a high rate.

Risk Factors

• Age & gender: Women <30 years old have a 2–3‑fold higher incidence than men.
• Family history: Genetic predisposition to conduction abnormalities.
• Structural heart disease: Congenital defects, cardiomyopathy, or prior heart surgery.
• Electrolyte disturbances: Low potassium or magnesium.
• Stimulants: Caffeine, nicotine, cocaine, or certain decongestants.
• Medications: Digoxin, certain anti‑arrhythmics, or asthma inhalers (beta‑agonists).
• Hyperthyroidism: Excess thyroid hormone accelerates heart rate.
• Stress & lack of sleep: Autonomic imbalance can precipitate SVT.

Diagnosis

Because SVT episodes can be brief, capturing the rhythm during an event is key. A systematic work‑up typically includes:

1. Clinical History & Physical Exam

• Characterization of palpitations (onset, duration, triggers)
• Review of medications, caffeine/alcohol intake, and family cardiac history
• Blood pressure and heart‑rate assessment during and between episodes

2. Electrocardiogram (ECG)

A 12‑lead ECG performed during an episode shows a narrow‑complex tachycardia (QRS ≤ 120 ms) at a regular rate of 150‑250 bpm. “P‑waves” may be hidden or abnormal, helping differentiate AVNRT from AVRT.

3. Ambulatory Monitoring

• Holter monitor (24–48 h): Captures frequent episodes.
• Event recorder or loop recorder (up to 30 days): Patient‑activated devices for sporadic episodes.
• Implantable cardiac monitor: For very infrequent but concerning arrhythmias.

4. Electrophysiology Study (EPS)

Invasive testing performed in a cardiac electrophysiology lab. Small catheters map the heart’s electrical pathways, confirm the SVT mechanism, and often allow immediate treatment (catheter ablation). EPS is recommended when:

• Symptoms are severe or refractory to medication
• There is suspicion of an accessory pathway (e.g., WPW)
• Non‑invasive tests are inconclusive

5. Laboratory Tests

Thyroid‑function tests, electrolyte panel, and drug screens help rule out reversible causes.

Treatment Options

Treatment is individualized based on episode frequency, severity, underlying heart disease, and patient preference.

1. Acute Management (terminating an ongoing episode)

• Vagal maneuvers:
  • Valsalva maneuver (bearing down as if having a bowel movement)
  • Cold‑water facial immersion (immersion goggles)
  • Carotid sinus massage – only by trained professionals
  Effective in ~20–30 % of AVNRT episodes (AHA/ACC 2023 guideline).
• Pharmacologic options:
  • Adenosine (6 mg rapid IV push, may repeat 12 mg) – the first‑line drug for rapid conversion.
  • Calcium‑channel blockers (verapamil or diltiazem) – IV or oral for slower conversion.
  • Beta‑blockers (metoprolol, propranolol) – useful if adenosine is contraindicated.
• Electrical cardioversion: Synchronized shock (100–200 J) if the patient is unstable (hypotensive, chest pain, syncope).

2. Long‑Term Management

Medications

• Beta‑blockers (e.g., atenolol, metoprolol) – Reduce sympathetic tone.
• Calcium‑channel blockers (e.g., verapamil, diltiazem) – Decrease AV‑node conduction.
• Anti‑arrhythmic agents (e.g., flecainide, propafenone, sotalol) – Reserved for refractory cases; require ECG monitoring.

Catheter Ablation

Minimally invasive radiofrequency or cryo‑ablation destroys the abnormal pathway. Success rates >95 % for AVNRT and 85–90 % for AVRT, with low complication rates (<2 %). Recommended for patients with:

• Frequent, symptomatic episodes despite medication
• Medication intolerance or contraindications
• Occupational demands where palpitations are unsafe (pilots, drivers)

Lifestyle Modifications

• Limit caffeine, alcohol, and nicotine.
• Stay hydrated—dehydration can precipitate SVT.
• Maintain a regular sleep schedule.
• Stress‑reduction techniques (mindfulness, yoga, biofeedback).
• Review all prescription and over‑the‑counter drugs with a clinician.

Living with Supraventricular Tachycardia (SVT)

Most people with SVT lead normal, active lives. Practical tips for daily management include:

• Keep a symptom diary: Note date, time, triggers, duration, and heart‑rate if you can measure it. This helps your provider tailor treatment.
• Learn and practice vagal maneuvers: Having them ready can abort an episode quickly.
• Carry an emergency card: List your diagnosis, medications, and any allergies.
• Stay active but listen to your body: Moderate aerobic exercise is beneficial; stop and rest if you feel palpitations.
• Inform close contacts: Family, coworkers, and coaches should know how to assist if an episode becomes severe.
• Regular follow‑up: Annual check‑ups or sooner if symptoms change.
• Insurance and medical records: Keep copies of ECGs, EPS reports, and procedure summaries.

Prevention

While you cannot always prevent an arrhythmia that has a genetic basis, you can reduce triggers and improve heart health:

• Limit stimulant intake (caffeine <300 mg/day, avoid energy drinks).
• Quit smoking and avoid illicit drugs.
• Control thyroid disease and correct electrolyte imbalances.
• Manage stress with relaxation training, CBT, or counseling.
• Maintain a heart‑healthy diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids.
• Stay hydrated, especially during hot weather or intense exercise.
• Review all new medications with your cardiologist before use.

Complications

Most SVT episodes are benign, but untreated or frequent SVT can lead to:

• Heart failure: Persistent tachycardia can weaken the myocardium (tachy‑cardiomyopathy).
• Syncope or falls: Due to sudden drops in blood pressure.
• Ischemic chest pain: Especially in patients with underlying coronary artery disease.
• Stroke: Rare, but possible if SVT is associated with atrial thrombus formation.
• Psychological impact: Anxiety or depression from unpredictable episodes.

Early diagnosis and appropriate treatment markedly lower these risks (Cleveland Clinic, 2022).

When to Seek Emergency Care

References

• Mayo Clinic. Supraventricular tachycardia (SVT). Updated 2023. https://www.mayoclinic.org
• American Heart Association / American College of Cardiology. 2023 Guideline for the Management of Supraventricular Arrhythmias. doi:10.1161/CIR.0000000000001348
• Cleveland Clinic. SVT – Diagnosis & Treatment. 2022. https://my.clevelandclinic.org
• Centers for Disease Control and Prevention. Cardiovascular Disease Statistics. 2022. https://www.cdc.gov
• National Institutes of Health, National Heart, Lung, and Blood Institute. Arrhythmia Overview. 2021. https://www.nhlbi.nih.gov
• World Health Organization. Non‑communicable diseases: Cardiovascular disorders. 2023. https://www.who.int

```